Journal article
Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
Abstract
PURPOSE: Four recent first-line clinical trials leveraging immune-oncology agents demonstrated an overall survival (OS) benefit relative to sunitinib. We aimed to provide formal comparisons among immune-oncology combinations in terms of OS, progression-free survival (PFS), objective response rates and treatment-related adverse events (AEs).
MATERIALS AND METHODS: PubMed® database was searched for studies indexed from January 1, 2016 through …
Authors
Nocera L; Karakiewicz PI; Wenzel M; Tian Z; Shariat SF; Saad F; Chun FKH; Briganti A; Kapoor A; Lalani A-K
Journal
Journal of Urology, Vol. 207, No. 1, pp. 16–24
Publisher
Wolters Kluwer
Publication Date
January 2022
DOI
10.1097/ju.0000000000002252
ISSN
0021-0005